Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
WHEN Pluristem Therapeutics Inc, an Israeli developer of experimental stem-cell treatments, rose 39 per cent in Nasdaq trading last week, traders attributed it to a bullish report on a website linked to a California biotech pundit.
The two-page report from Acceleron Equity...